Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2001

01-07-2001 | Revisiones

Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression

Authors: Joel M. Salazar Cavazos, Juan Francisco González Guerrero, William O. Brito Villanueva, Joan Albanell Mestres, José M. Baselga Torres

Published in: Clinical and Translational Oncology | Issue 4/2001

Login to get access
Metadata
Title
Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression
Authors
Joel M. Salazar Cavazos
Juan Francisco González Guerrero
William O. Brito Villanueva
Joan Albanell Mestres
José M. Baselga Torres
Publication date
01-07-2001
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2001
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02712688

Other articles of this Issue 4/2001

Clinical and Translational Oncology 4/2001 Go to the issue

Notas Clínicas

Neumonía por Pneumocystis carinii y cáncer de órgano sólido

Originales Breves

Deletion of the N-acetyltransferase-2 (NAT2) gene is an early-common event in the squamous cell carcinoma of the head and neck

Notas Clínicas

Sarcoma de Kaposi en un paciente con linfoma T periférico

Originales

Sacropelvic resection and intraoperative radiation therapy: feasibility, technical description and early clinical results

Originales

Vacunación idiotípica en linfomas B de bajo grado: una nueva terapia antitumoral

Revisiones

Chemotherapy-induced pulmonary toxicity in lung cancer management
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits